US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ArriVent BioPharma

20.90

+0.04000.19%

Post-market: 20.900.00000.00%16:02 EDT

Volume:194.14K

Turnover:4.05M

Market Cap:847.89M

PE:-5.20

High:21.08

Open:20.88

Low:20.49

Close:20.86

52wk High:36.37

52wk Low:15.47

Shares:40.57M

Float Shares:18.29M

Volume Ratio:0.58

T/O Rate:1.06%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.0162

EPS(LYR):-2.5577

ROE:-50.06%

ROA:-23.41%

PB:3.39

PE(LYR):-8.17

Loading ...

Overview Company News Filings

ArriVent Biopharma Inc. Appoints Brent S. Rice as Chief Commercial Officer

Arrivent Appoints Brent S. Rice as Chief Commercial Officer

THOMSON REUTERS

ArriVent Biopharma Unveils Promising Phase 1b Trial Results for Firmonertinib in EGFR Mutant Lung Cancer at 2025 World Conference on Lung Cancer

Arrivent Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary

Stock Track | ArriVent BioPharma Plunges 5.12% Amid Conflicting Analyst Reports

ArriVent BioPharma Q2 EPS $(0.90) Misses $(0.72) Estimate

ArriVent Biopharma Inc. Reports Q2 2025 Results: Net Loss Increases to $95.8M, Driven by Higher R&D Expenses

Arrivent Biopharma Inc: Q2 EPS $-0.90

THOMSON REUTERS

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

Arrivent Biopharma Inc expected to post a loss of 70 cents a share - Earnings Preview

ArriVent BioPharma Announces Completion of Enrollment for FURVENT Phase 3 Study, Topline Results Expected Early 2026

ArriVent BioPharma Price Target Announced at $33.00/Share by Goldman Sachs

ArriVent Biopharma Files Prospectus for $75 Million Public Offering of Common Stock and Pre-Funded Warrants

BUZZ-U.S. STOCKS ON THE MOVE-Investar, Steel Dynamics, Axos Financial

BUZZ-U.S. STOCKS ON THE MOVE-Zevra Therapeutics, Abeona Therapeutics, Greenbrier

BUZZ-ArriVent BioPharma drops after $75 mln equity raise

ArriVent BioPharma Plans $75 Million Public Offering

MT Newswires Live

BRIEF-Arrivent Proposes $75 Million Public Offering of Common Stock and Pre-Funded Warrants

ArriVent BioPharma Initiated at Buy by Clear Street

ArriVent BioPharma Price Target Maintained With a $45.00/Share by Guggenheim

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AVBP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","market":"US","secType":"STK","nameCN":"ArriVent BioPharma","latestPrice":20.9,"timestamp":1760385600000,"preClose":20.86,"halted":0,"volume":194143,"hourTrading":{"tag":"盘后","latestPrice":20.9,"preClose":20.9,"latestTime":"16:02 EDT","volume":6206,"amount":129705.4,"timestamp":1760385749321},"delay":0,"floatShares":18293400,"shares":40568944,"eps":-4.016159,"marketStatus":"Post-Mkt","change":0.04,"latestTime":"10-13 18:41:28 EDT","open":20.88,"high":21.075,"low":20.49,"amount":4047247.5444,"amplitude":0.028044,"askPrice":21.3,"askSize":20,"bidPrice":20.3,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.016159,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1760400000000},"marketStatusCode":4,"adr":0,"listingDate":1706245200000,"exchange":"NASDAQ","adjPreClose":20.86,"preHourTrading":{"tag":"盘前","latestPrice":20.86,"preClose":20.86,"latestTime":"08:00 EDT","volume":70,"amount":1460.2,"timestamp":1760356803881},"postHourTrading":{"tag":"盘后","latestPrice":20.9,"preClose":20.9,"latestTime":"16:02 EDT","volume":6206,"amount":129705.4,"timestamp":1760385749321},"volumeRatio":0.582224,"impliedVol":0.9897,"impliedVolPercentile":0.9767},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","floatShares":18293400,"roa":"-23.41%","roe":"-50.06%","lyrEps":-2.557665,"volumeRatio":0.582224,"shares":40568944,"dividePrice":0,"high":21.075,"amplitude":0.028044,"preClose":20.86,"low":20.49,"week52Low":15.47,"pbRate":"3.39","week52High":36.37,"institutionHeld":0,"latestPrice":20.9,"committee":0.666667,"eps":-4.016159,"divideRate":0,"volume":194143,"delay":0,"ttmEps":-4.016159,"open":20.88,"prevYearClose":26.64,"prevWeekClose":20.86,"prevMonthClose":18.45,"prevQuarterClose":18.45,"fiveDayClose":19.95,"twentyDayClose":18.95,"sixtyDayClose":22.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVBP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-11","symbol":"AVBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.7,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"pre","actualEps":-0.9},{"market":"US","date":"2025-05-12","symbol":"AVBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.66,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-1.9},{"market":"US","date":"2025-03-03","symbol":"AVBP","fiscalQuarterEnding":"2024/12","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740978000000,"reportTimeType":"pre","actualEps":-0.6},{"market":"US","date":"2024-11-14","symbol":"AVBP","fiscalQuarterEnding":"2024/09","expectedEps":-0.82,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-0.61}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":10,"updateTime":1753675200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AVBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AVBP","date":"2025-10-10","current":-5.203977,"percent":0.782927,"low":-15.980041,"twenty":-11.458565,"median":-8.908923,"eighty":-6.178119,"high":-4.80343,"avg":-9.169643,"sd":2.577423,"marketCap":857221786},"quantilePoints":[{"date":"2024-01-26","current":-15.452095,"twenty":-15.452095,"median":-15.452095,"eighty":-15.452095,"marketCap":905214654},{"date":"2024-02-02","current":-11.990156,"twenty":-12.001066,"median":-11.872873,"eighty":-10.91006,"marketCap":702407320},{"date":"2024-02-09","current":-12.548731,"twenty":-12.548731,"median":-12.001066,"eighty":-11.75559,"marketCap":735129780},{"date":"2024-02-16","current":-12.588659,"twenty":-12.548731,"median":-12.126596,"eighty":-11.919241,"marketCap":737468829},{"date":"2024-02-23","current":-11.219707,"twenty":-12.556717,"median":-11.998256,"eighty":-11.67237,"marketCap":657272853},{"date":"2024-03-01","current":-12.286349,"twenty":-12.548731,"median":-11.990156,"eighty":-11.204877,"marketCap":719758884},{"date":"2024-03-08","current":-11.464977,"twenty":-12.548731,"median":-11.964074,"eighty":-11.315533,"marketCap":671641299},{"date":"2024-03-15","current":-10.59227,"twenty":-12.5031,"median":-11.767288,"eighty":-11.121598,"marketCap":620516364},{"date":"2024-03-22","current":-10.386927,"twenty":-12.327418,"median":-11.658912,"eighty":-10.920492,"marketCap":608486967},{"date":"2024-03-28","current":-10.267144,"twenty":-12.279504,"median":-11.507757,"eighty":-10.718898,"marketCap":601469820},{"date":"2024-04-05","current":-8.84046,"twenty":-12.261251,"median":-11.265338,"eighty":-10.410884,"marketCap":612935625},{"date":"2024-04-12","current":-8.536116,"twenty":-12.10149,"median":-11.165519,"eighty":-9.961411,"marketCap":591834562},{"date":"2024-04-19","current":-7.487821,"twenty":-11.997694,"median":-11.025772,"eighty":-8.805678,"marketCap":519153125},{"date":"2024-04-26","current":-7.507145,"twenty":-11.992272,"median":-10.91658,"eighty":-8.501334,"marketCap":520492875},{"date":"2024-05-03","current":-8.115832,"twenty":-11.986485,"median":-10.803317,"eighty":-8.191193,"marketCap":562695000},{"date":"2024-05-10","current":-8.079495,"twenty":-11.960082,"median":-10.543786,"eighty":-8.115832,"marketCap":602552562},{"date":"2024-05-17","current":-9.049573,"twenty":-11.929189,"median":-10.386927,"eighty":-8.101297,"marketCap":674899062},{"date":"2024-05-24","current":-8.479203,"twenty":-11.828069,"median":-10.210104,"eighty":-8.115832,"marketCap":632362000},{"date":"2024-05-31","current":-8.739687,"twenty":-11.762609,"median":-9.361752,"eighty":-8.133223,"marketCap":651788375},{"date":"2024-06-07","current":-8.241175,"twenty":-11.7192,"median":-8.959751,"eighty":-8.180566,"marketCap":614610312},{"date":"2024-06-14","current":-8.456747,"twenty":-11.662334,"median":-8.912923,"eighty":-8.216398,"marketCap":630687312},{"date":"2024-06-21","current":-7.455231,"twenty":-11.653208,"median":-8.84046,"eighty":-8.15931,"marketCap":555996250},{"date":"2024-06-28","current":-7.81452,"twenty":-11.61214,"median":-8.79358,"eighty":-8.133223,"marketCap":582791250},{"date":"2024-07-05","current":-8.205246,"twenty":-11.533425,"median":-8.753505,"eighty":-8.152944,"marketCap":611930812},{"date":"2024-07-12","current":-8.268121,"twenty":-11.43988,"median":-8.706383,"eighty":-8.152944,"marketCap":616619937},{"date":"2024-07-15","current":-8.259139,"twenty":-11.414782,"median":-8.695535,"eighty":-8.154535,"marketCap":615950062},{"date":"2024-08-02","current":-9.655872,"twenty":-11.389685,"median":-8.706383,"eighty":-8.156127,"marketCap":720115625},{"date":"2024-08-09","current":-10.262171,"twenty":-11.294999,"median":-8.753505,"eighty":-8.186872,"marketCap":765332187},{"date":"2024-08-16","current":-10.701201,"twenty":-11.237959,"median":-8.81702,"eighty":-8.205246,"marketCap":801359406},{"date":"2024-08-23","current":-10.705686,"twenty":-11.199173,"median":-8.912923,"eighty":-8.209568,"marketCap":801695265},{"date":"2024-08-30","current":-12.010819,"twenty":-11.389685,"median":-8.993434,"eighty":-8.224295,"marketCap":899430214},{"date":"2024-09-06","current":-11.93009,"twenty":-11.657877,"median":-9.253918,"eighty":-8.235785,"marketCap":893384753},{"date":"2024-09-13","current":-10.669806,"twenty":-11.694732,"median":-9.655872,"eighty":-8.248361,"marketCap":799008394},{"date":"2024-09-20","current":-10.85369,"twenty":-11.663166,"median":-9.763659,"eighty":-8.262732,"marketCap":812778610},{"date":"2024-09-27","current":-10.544226,"twenty":-11.657877,"median":-10.060071,"eighty":-8.269917,"marketCap":789604344},{"date":"2024-10-04","current":-11.49056,"twenty":-11.61214,"median":-10.208101,"eighty":-8.279798,"marketCap":860470578},{"date":"2024-10-11","current":-12.463804,"twenty":-11.739278,"median":-10.315491,"eighty":-8.299559,"marketCap":933351966},{"date":"2024-10-18","current":-13.002004,"twenty":-11.938503,"median":-10.371883,"eighty":-8.317243,"marketCap":973655038},{"date":"2024-10-25","current":-13.912458,"twenty":-11.99333,"median":-10.426855,"eighty":-8.325491,"marketCap":1041834400},{"date":"2024-10-31","current":-14.114283,"twenty":-12.114871,"median":-10.539741,"eighty":-8.328911,"marketCap":1056948052},{"date":"2024-11-08","current":-15.980041,"twenty":-12.249611,"median":-10.573379,"eighty":-8.330997,"marketCap":1196665367},{"date":"2024-11-15","current":-11.674764,"twenty":-12.282511,"median":-10.59227,"eighty":-8.332793,"marketCap":946216280},{"date":"2024-11-22","current":-11.05527,"twenty":-12.272349,"median":-10.669806,"eighty":-8.342492,"marketCap":896007510},{"date":"2024-11-29","current":-12.456408,"twenty":-12.274941,"median":-10.685503,"eighty":-8.352544,"marketCap":1009566943},{"date":"2024-12-06","current":-11.870175,"twenty":-12.284404,"median":-10.712096,"eighty":-8.353452,"marketCap":962053946},{"date":"2024-12-13","current":-10.760075,"twenty":-12.274941,"median":-10.748293,"eighty":-8.371867,"marketCap":872082526},{"date":"2024-12-20","current":-10.664448,"twenty":-12.261979,"median":-10.759506,"eighty":-8.380399,"marketCap":864332179},{"date":"2024-12-27","current":-11.46688,"twenty":-12.254096,"median":-10.803317,"eighty":-8.380399,"marketCap":929367700},{"date":"2025-01-03","current":-11.421146,"twenty":-12.244582,"median":-10.85369,"eighty":-8.380399,"marketCap":925661012},{"date":"2025-01-10","current":-11.167527,"twenty":-12.234172,"median":-10.860965,"eighty":-8.382195,"marketCap":905105744},{"date":"2025-01-17","current":-10.177999,"twenty":-12.217129,"median":-10.850538,"eighty":-8.390279,"marketCap":824906501},{"date":"2025-01-24","current":-11.329677,"twenty":-12.196013,"median":-10.850538,"eighty":-8.405549,"marketCap":918247637},{"date":"2025-01-31","current":-12.09469,"twenty":-12.164539,"median":-10.860965,"eighty":-8.437266,"marketCap":980250413},{"date":"2025-02-07","current":-11.383727,"twenty":-12.161213,"median":-10.897572,"eighty":-8.450678,"marketCap":922628268},{"date":"2025-02-14","current":-11.16337,"twenty":-12.157147,"median":-10.9231,"eighty":-8.461238,"marketCap":904768772},{"date":"2025-02-21","current":-11.387884,"twenty":-12.140884,"median":-10.92545,"eighty":-8.479203,"marketCap":922965239},{"date":"2025-02-28","current":-9.8537,"twenty":-12.107163,"median":-10.91658,"eighty":-8.519623,"marketCap":798622715},{"date":"2025-03-07","current":-9.217439,"twenty":-12.09469,"median":-10.885085,"eighty":-8.536116,"marketCap":741893256},{"date":"2025-03-14","current":-9.192082,"twenty":-12.065586,"median":-10.857328,"eighty":-8.618427,"marketCap":739852284},{"date":"2025-03-21","current":-8.258082,"twenty":-12.010819,"median":-10.847386,"eighty":-8.519623,"marketCap":664676489},{"date":"2025-03-28","current":-7.848136,"twenty":-12.001066,"median":-10.781696,"eighty":-8.449161,"marketCap":631680778},{"date":"2025-04-04","current":-7.159258,"twenty":-11.995446,"median":-10.737081,"eighty":-8.380399,"marketCap":576234377},{"date":"2025-04-11","current":-7.125448,"twenty":-11.990156,"median":-10.711139,"eighty":-8.353452,"marketCap":573513081},{"date":"2025-04-17","current":-7.564978,"twenty":-11.988746,"median":-10.703443,"eighty":-8.330997,"marketCap":608889926},{"date":"2025-04-25","current":-8.94696,"twenty":-11.984909,"median":-10.669806,"eighty":-8.330476,"marketCap":720122890},{"date":"2025-05-02","current":-8.908923,"twenty":-11.976101,"median":-10.6604,"eighty":-8.330997,"marketCap":717061432},{"date":"2025-05-09","current":-8.353948,"twenty":-11.95416,"median":-10.580862,"eighty":-8.330997,"marketCap":672392561},{"date":"2025-05-16","current":-5.164444,"twenty":-11.945123,"median":-10.566696,"eighty":-8.323142,"marketCap":658249673},{"date":"2025-05-23","current":-5.537551,"twenty":-11.932894,"median":-10.539741,"eighty":-8.281274,"marketCap":705805133},{"date":"2025-05-30","current":-5.636867,"twenty":-11.923581,"median":-10.506711,"eighty":-8.258716,"marketCap":718463781},{"date":"2025-06-06","current":-6.29987,"twenty":-11.889801,"median":-10.45834,"eighty":-8.241176,"marketCap":802968806},{"date":"2025-06-13","current":-6.342817,"twenty":-11.86768,"median":-10.37894,"eighty":-8.205246,"marketCap":808442816},{"date":"2025-06-20","current":-6.681029,"twenty":-11.831093,"median":-10.360937,"eighty":-8.13004,"marketCap":851550643},{"date":"2025-06-27","current":-6.122711,"twenty":-11.774139,"median":-10.336565,"eighty":-8.056606,"marketCap":780388516},{"date":"2025-07-03","current":-5.951741,"twenty":-11.764948,"median":-10.291317,"eighty":-8.012114,"marketCap":758596999},{"date":"2025-07-11","current":-6.3128,"twenty":-11.752729,"median":-10.177999,"eighty":-7.877518,"marketCap":804616846},{"date":"2025-07-18","current":-6.510523,"twenty":-11.737545,"median":-10.15098,"eighty":-7.814365,"marketCap":829818191},{"date":"2025-07-25","current":-6.146598,"twenty":-11.721024,"median":-10.060071,"eighty":-7.74746,"marketCap":783433107},{"date":"2025-08-01","current":-5.590682,"twenty":-11.706801,"median":-9.819907,"eighty":-7.667253,"marketCap":712577152},{"date":"2025-08-08","current":-5.312724,"twenty":-11.672734,"median":-9.759167,"eighty":-7.57343,"marketCap":677149175},{"date":"2025-08-15","current":-5.522288,"twenty":-11.663891,"median":-9.64689,"eighty":-7.464633,"marketCap":755393737},{"date":"2025-08-22","current":-5.895976,"twenty":-11.659587,"median":-9.496371,"eighty":-7.205647,"marketCap":806510606},{"date":"2025-08-29","current":-5.697269,"twenty":-11.653822,"median":-9.38434,"eighty":-6.898922,"marketCap":779329414},{"date":"2025-09-05","current":-5.789208,"twenty":-11.653208,"median":-9.260758,"eighty":-6.705187,"marketCap":791905786},{"date":"2025-09-12","current":-5.640919,"twenty":-11.550537,"median":-9.192082,"eighty":-6.342817,"marketCap":771621314},{"date":"2025-09-19","current":-5.510425,"twenty":-11.49056,"median":-9.038346,"eighty":-6.3128,"marketCap":753770979},{"date":"2025-09-26","current":-5.092249,"twenty":-11.46688,"median":-8.984996,"eighty":-6.266951,"marketCap":696568768},{"date":"2025-10-03","current":-5.584569,"twenty":-11.464977,"median":-8.939882,"eighty":-6.203238,"marketCap":763913215},{"date":"2025-10-10","current":-6.266699,"twenty":-11.458565,"median":-8.908923,"eighty":-6.178119,"marketCap":857221786}],"updateTime":1760395288137},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVBP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2569730393","title":"ArriVent Biopharma Inc. Appoints Brent S. Rice as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2569730393","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569730393?lang=en_us&edition=fundamental","pubTime":"2025-09-23 04:05","pubTimestamp":1758571510,"startTime":"0","endTime":"0","summary":"ArriVent Biopharma Inc. has appointed Brent S. Rice as Chief Commercial Officer. Rice brings over 25 years of experience in the biotechnology and pharmaceutical industry. He joins ArriVent from Autolus Therapeutics Ltd., where he served as Senior Vice President and global Chief Commercial Officer, leading the launch of their first commercial product. At ArriVent, Rice will focus on commercializing the company's pipeline, including firmonertinib for EGFR mutant non-small cell lung cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on September 22, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nNDLjF4qR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4139","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4588","LU2210150020.SGD","IE00B64PRP62.GBP","AVBP","NDAQ","IE00BKPKM429.USD","BK4585","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2569730368","title":"Arrivent Appoints Brent S. Rice as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2569730368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569730368?lang=en_us&edition=fundamental","pubTime":"2025-09-23 04:05","pubTimestamp":1758571500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nTUA1KW6DJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2566694704","title":"ArriVent Biopharma Unveils Promising Phase 1b Trial Results for Firmonertinib in EGFR Mutant Lung Cancer at 2025 World Conference on Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2566694704","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566694704?lang=en_us&edition=fundamental","pubTime":"2025-09-09 20:01","pubTimestamp":1757419300,"startTime":"0","endTime":"0","summary":"ArriVent Biopharma Unveils Promising Phase 1b Trial Results for Firmonertinib in EGFR Mutant Lung Cancer at 2025 World Conference on Lung Cancer. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 09, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL18CxQ8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2559529604","title":"Arrivent Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2559529604","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559529604?lang=en_us&edition=fundamental","pubTime":"2025-08-13 19:59","pubTimestamp":1755086393,"startTime":"0","endTime":"0","summary":"Arrivent Biopharma Inc reports results for the quarter ended June 30 - Earnings SummaryArrivent Biopharma Inc AVBP.OQ reported a quarterly adjusted loss of 90 cents per share for the quarter ended Jun","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nL8N3U50RC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"1189048375","title":"Stock Track | ArriVent BioPharma Plunges 5.12% Amid Conflicting Analyst Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=1189048375","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189048375?lang=en_us&edition=fundamental","pubTime":"2025-08-12 22:37","pubTimestamp":1755009422,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) shares plummeted 5.12% in Tuesday's trading session, as investors grappled with conflicting analyst reports. The significant drop comes as Wall Street analysts provided...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AVBP"],"gpt_icon":0},{"id":"2558650624","title":"ArriVent BioPharma Q2 EPS $(0.90) Misses $(0.72) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2558650624","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558650624?lang=en_us&edition=fundamental","pubTime":"2025-08-11 20:12","pubTimestamp":1754914348,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.72) by 25.52 percent. This is a 38.46 percent decrease over losses of $(0.65) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47028207/arrivent-biopharma-q2-eps-0-90-misses-0-72-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"2558525650","title":"ArriVent Biopharma Inc. Reports Q2 2025 Results: Net Loss Increases to $95.8M, Driven by Higher R&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2558525650","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558525650?lang=en_us&edition=fundamental","pubTime":"2025-08-11 20:00","pubTimestamp":1754913643,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on August 11, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nNDL5t7dFh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210150020.SGD","BK4588","LU2095319765.USD","AVBP","NDAQ","IE00BKPKM429.USD","LU0314104364.USD","BK4112","LU2210149790.SGD","BK4585","IE00BGHQF748.EUR","BK1161","BK4139","02157","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2558951650","title":"Arrivent Biopharma Inc: Q2 EPS $-0.90","url":"https://stock-news.laohu8.com/highlight/detail?id=2558951650","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558951650?lang=en_us&edition=fundamental","pubTime":"2025-08-11 20:00","pubTimestamp":1754913604,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nTUA9DD633:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2558573650","title":"ArriVent BioPharma Reports Second Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2558573650","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558573650?lang=en_us&edition=fundamental","pubTime":"2025-08-11 20:00","pubTimestamp":1754913600,"startTime":"0","endTime":"0","summary":"Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patien","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/11/3130840/0/en/ArriVent-BioPharma-Reports-Second-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4080","PACC","ADC","AVBP","BK4139"],"gpt_icon":0},{"id":"2558541176","title":"Arrivent Biopharma Inc  expected to post a loss of 70 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2558541176","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558541176?lang=en_us&edition=fundamental","pubTime":"2025-08-11 19:03","pubTimestamp":1754910188,"startTime":"0","endTime":"0","summary":"Arrivent Biopharma Inc  expected to post a loss of70cents a share - Earnings Preview Arrivent Biopharma Inc AVBP.OQ AVBP.O is expected to  show no change in quarterly revenue when it reports  results ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nL8N3U30HG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"2553471499","title":"ArriVent BioPharma Announces Completion of Enrollment for FURVENT Phase 3 Study, Topline Results Expected Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2553471499","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553471499?lang=en_us&edition=fundamental","pubTime":"2025-07-21 20:09","pubTimestamp":1753099767,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma Inc., a clinical-stage company focused on the global development of biopharmaceutical therapeutics, has announced that topline data from the FURVENT Phase 3 study of firmonertinib monotherapy in first-line EGFR exon20 insertion mutant non-small cell lung cancer  is projected to be available in early 2026. The study, which completed enrollment in the first quarter of 2025, aims to assess progression free survival  by blinded independent central review according to RECIST 1.1 criteria. Firmonertinib has previously received FDA Breakthrough Therapy Designation for this patient population, highlighting the potential significance of the upcoming data. The results of the FURVENT study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nNDLcf3pWP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2550678415","title":"ArriVent BioPharma Price Target Announced at $33.00/Share by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2550678415","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550678415?lang=en_us&edition=fundamental","pubTime":"2025-07-11 02:24","pubTimestamp":1752171840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 10, 2025 14:24 ET (18:24 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"2548484858","title":"ArriVent Biopharma Files Prospectus for $75 Million Public Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2548484858","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548484858?lang=en_us&edition=fundamental","pubTime":"2025-07-03 05:01","pubTimestamp":1751490073,"startTime":"0","endTime":"0","summary":"ArriVent Biopharma Inc., a clinical-stage biopharmaceutical company, has announced the pricing of a $75 million public offering of common stock and pre-funded warrants. The company has filed an automatic shelf registration statement on Form S-3ASR with the SEC, which became effective upon filing on February 3, 2025. The offering includes 2,482,692 shares of common stock priced at $19.50 each and pre-funded warrants for an additional 1,363,469 shares. The proceeds are intended to support the company's pipeline programs and general corporate purposes. The offering, expected to close around July 3, 2025, is managed by Goldman Sachs, Citigroup, and Guggenheim Securities, among others.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nNDL3VqdP3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1668664300.SGD","LU2237443465.HKD","LU1201861249.SGD","LU0130517989.USD","LU2125154935.USD","IE0004086264.USD","LU0648001328.SGD","LU0320765646.SGD","LU2237443549.SGD","BK4566","BK4504","IE0004091025.USD","BK4559","LU1791807156.HKD","BK4127","LU2360032135.SGD","LU1366192091.USD","LU0096364046.USD","LU0106831901.USD","BK4207","LU0742534661.SGD","LU1894683348.USD","IE0002270589.USD","LU2462157665.USD","AVBP","LU0170899867.USD","IE00BFXG1179.USD","LU0072461881.USD","LU1267930227.SGD","BK4550","LU1868836757.USD","LU0310800965.SGD","LU0048573561.USD","LU2456880835.USD","BK4139","LU2237443382.USD","BK4534","LU0098860793.USD","LU0251142724.SGD","LU1868836591.USD","BK4533","LU0477156953.USD","LU1868837300.USD","LU1894683264.USD","LU0162691827.USD","LU2237443895.HKD","LU2236285917.USD","LU1868837136.USD","LU2417539215.USD","BK4552"],"gpt_icon":0},{"id":"2548141158","title":"BUZZ-U.S. STOCKS ON THE MOVE-Investar, Steel Dynamics, Axos Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2548141158","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548141158?lang=en_us&edition=fundamental","pubTime":"2025-07-03 02:00","pubTimestamp":1751479228,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Investar, Steel Dynamics, Axos FinancialEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nL6N3SZ0DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALV","CVNA","ISTR","OMDA","PRMB","AVBP","SCCO","ZVRA","ELV","FSLR","AX","UAA","VRNT","XOM","DNTH","KBR","ANF","EQT","GBX","CAVA","CVX","BMRC","FCX","RIVN","JBL","VFC","OGN","ABM","GEV","NUE","CARG","STZ","REGN","ABEO","DFDV","MO","SPOT","CNC","STLD","ROST","APA"],"gpt_icon":1},{"id":"2548897651","title":"BUZZ-U.S. STOCKS ON THE MOVE-Zevra Therapeutics, Abeona Therapeutics, Greenbrier","url":"https://stock-news.laohu8.com/highlight/detail?id=2548897651","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548897651?lang=en_us&edition=fundamental","pubTime":"2025-07-02 21:10","pubTimestamp":1751461853,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Zevra Therapeutics, Abeona Therapeutics, GreenbrierEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nL6N3SZ0D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCCO","ZVRA","RIO.AU","DFDV","LU1551013425.SGD","LU1883866441.USD","LU2430703251.USD","LU2290526834.HKD","IE00BQXX3D17.EUR","LU0122376428.USD","LU1267930227.SGD","BK4507","FCX","XOM","LU2108987350.USD","CVX","LU0738911758.USD","LU2746668461.USD","OGN","JBL","ELV","LU2028103732.USD","LU2324357040.USD","CAVA","LU0612318385.USD","LU2125154935.USD","SPOT","LU0149725797.USD","OMDA","GBX","CVNA","ABEO","EQT","LU0823434740.USD","APA","ALV","BHP.AU","STZ","LU2213496289.HKD","AVBP","RIO.UK","ROST","CNC","LU1084165304.USD","MO"],"gpt_icon":1},{"id":"2548889959","title":"BUZZ-ArriVent BioPharma drops after $75 mln equity raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2548889959","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548889959?lang=en_us&edition=fundamental","pubTime":"2025-07-02 19:25","pubTimestamp":1751455515,"startTime":"0","endTime":"0","summary":"BUZZ-ArriVent BioPharma drops after $75 mln equity raise** ArriVent BioPharma's AVBP.O shares down 4.3% premarket at $20 after overnight follow-on priced** Newtown Square, Pennsylvania-based late Tues announced ~3.8 mln shares, including pre-funded warrants to buy ~1.4 mln shares, for $75 mln gross proceeds** Offering price of $19.50 is 6.7% discount to stock's last sale** Co to use net proceeds to support activities for lead candidate, firmonertinib, its treatment for non-small cell lung cancer, and other pipeline programs, among other general purposes** Goldman Sachs, Citigroup and Guggenheim are jt bookrunners for offering** ArriVent has ~34.2 mln shares outstanding for ~$715 mln market cap** AVBP shares on Tues fell 4% to $20.89, stretching YTD loss to ~22%** All 8 analysts are bullish on AVBP with avg rating of \"strong buy\" and median PT is $40, latest LSEG data reflects","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nL6N3SZ0G7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU0061475181.USD","LU1894683348.USD","BK4127","AVBP","LU1868836591.USD","BK4550","LU0052756011.USD","LU0130517989.USD","LU0162691827.USD","LU1791807156.HKD","LU2750360641.GBP","LU2417539215.USD","LU2471134523.USD","LU0742534661.SGD","IE0004091025.USD","LU0106831901.USD","LU2125154935.USD","IE00BSNM7G36.USD","LU0477156953.USD","LU2237443382.USD","LU2360032135.SGD","LU0980610538.SGD","BK4585","LU0310800965.SGD","LU2236285917.USD","LU0251131958.USD","LU2237443465.HKD","LU1267930227.SGD","IE0034235188.USD","LU1868836757.USD","LU1868837136.USD","BK4516","LU0130102774.USD","LU2471134796.USD","LU0320765646.SGD","LU2237443622.USD","BK4139","BK4552","BK4559","LU0096364046.USD","LU0648001328.SGD","LU1366192091.USD","LU2237438978.USD","LU2237443549.SGD","LU0170899867.USD","LU0098860793.USD","LU1894683264.USD","LU1201861249.SGD","BK4588"],"gpt_icon":0},{"id":"2548865887","title":"ArriVent BioPharma Plans $75 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2548865887","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548865887?lang=en_us&edition=fundamental","pubTime":"2025-07-02 04:24","pubTimestamp":1751401496,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma  said late Tuesday it plans a $75 million public offering of common shares and pre-funded warrants.The company said it will offer underwriters a 30-day overallotment option to buy up to an additional 15% of the total offering size.ArriVent will use the net proceeds to advance activities related to its firmonertinib drug to treat non-squamous non-small cell lung cancer, as well as for general corporate purposes, the company said.Shares of the company fell 5.7% during after-hours activity.Price: 19.70, Change: -1.19, Percent Change: -5.70","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2548444882","title":"BRIEF-Arrivent Proposes $75 Million Public Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2548444882","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548444882?lang=en_us&edition=fundamental","pubTime":"2025-07-02 04:11","pubTimestamp":1751400701,"startTime":"0","endTime":"0","summary":"BRIEF-Arrivent Proposes $75 Million Public Offering of Common Stock and Pre-Funded WarrantsJuly 1 (Reuters) - Arrivent Biopharma Inc AVBP.O:ARRIVENT ANNOUNCES PROPOSED $75 MILLION PUBLIC OFFERING OF C","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nTUA2QT3PW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2546401872","title":"ArriVent BioPharma Initiated at Buy by Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2546401872","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546401872?lang=en_us&edition=fundamental","pubTime":"2025-06-26 01:37","pubTimestamp":1750873020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 25, 2025 13:37 ET (17:37 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2545287189","title":"ArriVent BioPharma Price Target Maintained With a $45.00/Share by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2545287189","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545287189?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:48","pubTimestamp":1750769280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 24, 2025 08:48 ET (12:48 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}]}}